Challenges in collecting, accessing and evaluating...[Thromb Res. 2005]

SearchDatabase nameforSearch term

Advanced Search

Your browser version may not work well with NCBI's Web applications. More information here...

Display Show

All: 1

Review: 0

Click to change filter selection through MyNCBI.

1: Thromb Res. 2005;117(1-2):137-44; discussion 145-51. Epub 2005 Sep 1. Links

Challenges in collecting, accessing and evaluating post market surveillance AERS in patients receiving dietary supplements.

Kingston R.

Regulatory and Scientific Affairs, Safety Call International Poison Center, 8009 34th Ave South, Suite 875, Bloomington, MN 55425, USA. rkingston@safetycall.com

PMID: 16139875 [PubMed - indexed for MEDLINE]

Adverse drug reactions and reporting.
Clin J Oncol Nurs. 2000 Jul-Aug; 4(4):181, 184.

[Clin J Oncol Nurs. 2000]
ReviewA primer of drug safety surveillance: an industry perspective. Part III: Managing adverse-event data.
J Pharm Technol. 1992 Nov-Dec; 8(6):259-73.

[J Pharm Technol. 1992]
ReviewThe state of dietary supplement adverse event reporting in the United States.
Pharmacoepidemiol Drug Saf. 2008 Oct; 17(10):962-70.

[Pharmacoepidemiol Drug Saf. 2008]
The role of databases in drug postmarketing surveillance.
Pharmacoepidemiol Drug Saf. 2001 Aug-Sep; 10(5):407-10.

[Pharmacoepidemiol Drug Saf. 2001]
FDA's response to food, dietary supplement, and cosmetic adverse events.
FDA Consum. 2003 Jul-Aug; 37(4):12-3.

[FDA Consum. 2003]
» See reviews... | » See all...

Recent Activity

Clear Turn Off Turn On

Challenges in collecting, accessing and evaluating post market surveillance AERS in patien...Challenges in collecting, accessing and evaluating post market surveillance AERS in patients receiving dietary supplements.

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Display Show

Challenges in collecting, accessing and evaluating post market surveillance AERS in patients receiving dietary supplements.

Related articles

Recent Activity